The potential role of *Limosilactobacillus fermentum* as a probiotic with anti-diabetic properties: A review

Lacerda DC et al. *L. fermentum* in diabetes

Diego Cabral Lacerda, Paulo Trindade da Costa, Paula Brielle Pontes, Lucas Santos, José Patrocínio Cruz Neto, Cristiane Silva Luis, Vanessa Polyana Sousa Brito, José Luiz de Brito Alves

**Abstract**

Oxidative stress, inflammation, and gut microbiota impairments have been implicated in the development and maintenance of diabetes mellitus. Strategies capable of recovering the community of commensal gut microbiota and controlling diabetes mellitus have increased in recent years. Some lactobacilli strains have an antioxidant and anti-inflammatory system capable of protecting against oxidative stress, inflammation, and diabetes mellitus. Experimental studies and some clinical trials have demonstrated that *Limosilactobacillus fermentum* strains can beneficially modulate the host antioxidant and anti-inflammatory system, resulting in the amelioration of glucose homeostasis in diabetic conditions. This review presents and discusses the currently available studies on the identification of *Limosilactobacillus fermentum* strains with anti-diabetic properties, their sources, range of dosage, and the intervention time in experiments with animals and clinical trials. This review strives to serve as a relevant and well-cataloged reference of *Limosilactobacillus fermentum* strains capable of inducing anti-diabetic effects and promoting health benefits.
**Key Words:** Diabetes Mellitus; Probiotics; *Limosilactobacillus fermentum*


**Core Tip:** This review strives to serve as a relevant and well-cataloged reference of *L. fermentum* strains with aptitudes of inducing anti-diabetic effects and health-promoting benefits to the host envisaging their wide applicability to diabetes control.

**INTRODUCTION**

Diabetes mellitus (DM) is a chronic non-communicable disease that affects millions of people and has become one of the leading causes of death worldwide. The Diabetes Atlas published by the International Diabetes Federation estimated that 537 million adults worldwide had type DM in 2021. Associated to this prevalence, clinical management of DM has elevated the costs of the health system, increasing by 316% in the last 15 years. One of the etiological factors of this metabolic disorder includes long-term inappropriate diet such as regular consumption of sugary drinks, red meat, and low consumption of whole grains and fiber. In addition, smoking, physical inactivity, history of gestational diabetes or delivery of newborns > 4 kg weight, medications such as statins, thiazides, and beta-blockers, psychosocial stress, and depression have been described as risk factors for DM.

Clinical features and laboratory findings of DM include changes in body weight, increased blood glucose, insulin resistance, development of lipid metabolism disorder, polyuria, polydipsia, visual disturbances, ketoacidosis, and hyperosmolar non-ketoacidotic syndrome with risk of coma. When uncontrolled, diabetes can induce grave complications, including death. Insulin resistance in sensitive tissues such as liver, muscle, and adipose tissue and β-cell dysfunctions are the main factors involved...
in initiating and progressing the pathophysiology of type 2 DM\textsuperscript{[5,11]}. Moreover, it has been reported that gut microbiota (GM) impairment plays a crucial role in developing DM\textsuperscript{[12]}.

DM patients show an altered intestinal microbiota resulting from an increase in opportunistic bacteria and Gram-negative toxin-producing bacteria that alter metabolism energetic\textsuperscript{[13]}. Furthermore, the accumulation of gut-derived pro-inflammatory molecules, including lipopolysaccharide (LPS), peptidoglycans, and flagellin, appear to accelerate the inflammatory response in patients with DM\textsuperscript{[14,15]}. Deregulation of the GM, also called dysbiosis, promotes intestinal permeability and energy homeostasis changes, causing metabolic endotoxemia, inflammation, hyperglycemia, and hyperlipidemia\textsuperscript{[16,17]}. Dysbiosis impairs the integrity of the intestinal wall and allows the translocation of toxins from the intestinal lumen into the systemic circulation, promoting inflammation, autoimmunity, and oxidative stress that can lead to β-cell destruction or insulin resistance\textsuperscript{[18,19]}.

The findings involving the association between gut dysbiosis and DM reinforce the importance of gut-targeting approaches in the treatment of DM\textsuperscript{[20-23]}. Strategies capable of recovering the community of commensal GM and controlling DM have recently increased. Probiotic therapy has begun to be used to improve GM composition and management of DM\textsuperscript{[23-25]}. Given this scenario, the identification of new potentially-probiotic strains with anti-diabetic properties is essential for the development of new probiotic products and testing in well-controlled trials.

Among \textit{Lactobacillus} species, strains of \textit{Limosilactobacillus fermentum} (\textit{L. fermentum}) has been reported to exert probiotic properties due to its ability to improve GM composition, reduce blood cholesterol, modulate the intestinal immune system, stimulate the release of immunoglobulin A, reduce intestinal inflammation, and increase the activity of antioxidant enzymes\textsuperscript{[26-30]}. Although early studies have identified anti-diabetic properties in some \textit{L. fermentum} strains, an in-depth review focusing on \textit{L. fermentum} strains as a potential anti-diabetic has not been found in the available literature to the time of this writing\textsuperscript{[31,32]}. 
This present literature review focuses on the emerging findings of experimental and clinical studies that have used *L. fermentum* supplementation to prevent or treat complications of DM. To investigate the effectiveness of *L. fermentum* more thoroughly, we focus on the type of strain, source of probiotics, dosage, duration of treatment, and the primary outcomes reported.

PROBIOTIC THERAPY IN THE TREATMENT OF METABOLIC DISORDERS

Probiotics are live microorganisms that confer host health benefits when administrated adequately. Probiotics have significant importance in the industrial economy and are among the most consumed food supplements worldwide\[^{33}\]. Experimental studies and clinical trials have documented that probiotics can modulate the GM, inducing beneficial effects and increasing overall wellness\[^{31,34,35}\]. Over the last few years, studies on probiotics have been growing sharply due to their beneficial health effects, which have been used as adjuvant therapy for metabolic disorders\[^{36}\]. A number of preclinical and clinical studies have investigated the effectiveness of probiotics by evaluating the intestinal microbiota after probiotics use, showing promising results in treating metabolic diseases\[^{34}\].

Impairment in commensal homeostasis of GM and intestinal functional capacity, called gut dysbiosis, is associated with the development of metabolic diseases such as colitis, obesity, liver, obesity, and DM\[^{23}\]. Thus, a probiotic may able to relieve GM dysbiosis, through various mechanisms including improvement in the composition and diversity of the GM, induction of immunomodulation, protection against physiological stress, and pathogen suppression\[^{23,37}\]. Probiotics also promote health benefits to the host through other mechanisms of action, such as the production of organic acids, including lactic acid and short-chain fatty acids (SCFA) (mainly acetate, propionate, and butyrate)\[^{38}\]. Another mechanism reported is the capacity of probiotics to protect the integrity of the intestinal wall by stimulating mucin production and upregulating tight-junction claudin, occludin, and zonulin protein expression\[^{39}\]. Furthermore, probiotics are also responsible for producing small molecules with systemic effects essential for
maintaining vital functions, such as cortisol, serotonin, gamma-aminobutyric acid (GABA), tryptophan, histamine derivatives, satiety hormones, and conjugated linoleic acid\[38\].

Coupled with the mechanisms mentioned above, some experimental and clinical evidence has demonstrated that probiotics have anti-inflammatory and antioxidant properties\[29,40,41\]. This antioxidant capacity results from signaling pathways that produce antioxidant enzymes and molecules, reducing serum and tissues levels of oxidative stress\[42,43\]. Concerning their anti-inflammatory properties, probiotics have been reported to reduce inflammatory markers, including LPS, tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, as well as to promote an increase of anti-inflammatory markers, such as IL-10.

**LIMOSILACTOBACILLUS FERMENTUM, LEAKY GUT AND DIABETES MELLITUS**

Probiotics have shown satisfactory results as an adjunct treatment in DM\[44\]. Both single strain, combined with other foods, and multiple strain probiotics can be used as supplements. Among more effective probiotic strains, the therapeutic potential of *L. fermentum* has been investigated for adjuvant management of DM\[45\].

*L. fermentum* is a Gram-positive, rod- or coccoid-shaped, heterofermentative, and anaerobic or aerotolerant bacteria found in fermented cereals and other fermenting plant materials, dairy products, manure sewage and feces, and the human vagina\[46\]. The *Lactobacillus* genus is widely used as an intestinal modulator due to its safety and probiotic activity\[47\]. Among these bacterial groups, *L. fermentum* is a well-studied species, mainly due to its action in improving metabolic function and oxidative stress, which may be considered for DM management\[28,29,48,49\].

DM is one of the main metabolic diseases related to leaky gut, oxidative stress, and chronic inflammation. GM impairment has been described in the pathogenesis of DM and metabolic syndrome. Due to the high mortality rate of patients with DM and this direct relationship with intestinal health, the number of studies involving probiotic
therapy has increased in recent years. *L. fermentum* has been proven to alleviate metabolic disorder-related symptoms, including improvement in glucose and insulin levels, control of the lipid profile, to decrease in pro-inflammatory cytokines and to increase antioxidant capacity\[^{29,46,50}\]. However, these protective responses need to be further investigated in clinical studies to elucidate the responsiveness of *L. fermentum* therapy in DM patients.

Most diabetes treatments, particularly drug therapies, use agents that act directly on signaling pathways to regulate glucose. Because of this, it is pertinent to explore therapies that adjunctively attenuate deregulation of GM, such as probiotics\[^{51}\]. Among the main harmful effects in GM induced by DM, gram-negative bacteria in the colon increase the concentration of LPS in the lumen. LPS causes high production of free radicals, increasing intestinal permeability and generating a systemic chronic inflammatory process. This pro-inflammatory state is a critical mechanism in the genesis of chronic diseases, such as DM\[^{45}\]. Additionally, GM imbalances observed in DM patients are characterized by changes in the composition of SCFAs, including increasing acetate levels and decreasing butyrate production. As a consequence, there may be acetate excess and reduction of butyrate, caused by dysbiosis, increased hepatic gluconeogenesis and impaired blood glucose homeostasis\[^{52}\].

On the other hand, *L. fermentum* manipulation could attenuate GM imbalance, which may decrease DM complications. Considering the inversely proportional relationship between butyrate and acetate levels and the effects of excess acetate on the worsening of DM, keeping these fatty acids in balance becomes an important way to assist glycemic control\[^{52}\]. Increased butyrate production by *L. fermentum* regulates acetate production, preventing increased hepatic gluconeogenesis and insulin resistance. Additionally, the increase in butyrate production resulting from *L. fermentum* supplementation may repair enterocyte tight junctions and improve intestinal permeability\[^{53}\]. Experimental evidence has revealed that increasing levels of SCFA, especially butyrate, decreases cellular damage of enterocytes, leading to a reduction in inflammation state, oxidative stress, and leaky gut in DM-induced rodents\[^{52,54}\].
Another antidiabetic property of *L. fermentum* is to maintain normal levels of the intestinal hormone GLP-1\[^{55}\]. GLP-1 has been shown to stimulate proliferation and prevent apoptosis of pancreatic beta cells, upregulating insulin synthesis and promoting a reasonable glycemic control\[^{32,39}\]. In the liver, GLP1 decreases gluconeogenesis and stimulates glycolysis, contributing to reducing glycemic levels in individuals with DM. GLP-1 is synthesized in enterocytes, so it is essential to maintain the integrity of the intestinal mucosa to ensure the production of this hormone. However, intestinal hyperpermeability found in patients with DM decreased output of the anorectic hormones GLP-1 and Peptide YY. The main consequence of reducing these peptides is the exacerbation of hunger, the search for palatable food, and the preference for hypercaloric foods, which can be a predisposing factor for developing obesity and insulin resistance\[^{32}\]. Leaky gut also generates chronic low-grade inflammation in organs such as the liver, skeletal muscle, and adipose tissue, causing metabolic changes such as hyperglycemia and dyslipidemias. *L. fermentum* also promotes benefits in these organs because it stimulates the synthesis of the fasting-induced adipose factor, a protein that regulates the function of the LPL enzyme and prevents hepatic steatosis and dyslipidemia, common in diabetic subjects\[^{56}\]. Therefore, it is suggested that *L. fermentum* may improve intestinal permeability, normalize GLP-1 Levels, and reduce DM complications.

Another important action of *L. fermentum* is to reduce oxidative stress and glycation. Studies indicate that pathophysiological findings of DM, including macular degeneration, vascular endothelial injury, hepatic fibrosis, renal failure, are related to the glycation process. This process occurs when circulating glucose binds to proteins, inactivating them and increasing inflammatory cytokines such as interferon-gamma (IFN-\(\gamma\)), IL-6, and IL-4. The main biochemical marker for glycation is glycated hemoglobin (Hb1ac), but this process can occur with any protein, including antioxidant enzymes. When glycation events occur more expressively, oxidative stress is even higher due to the increase in reactive oxygen species (ROS) and inactivation of the
enzymatic antioxidant systems, such as superoxide dismutase (SOD) and glutathione peroxidase.[42,58]

Conversely, the administration of *L. fermentum* decreased the glycation events and oxidative stress through the increasing production of ferulic acid (FA). This potent antioxidant metabolite can significantly reduce ROS formation and prevent glycation events. This mechanism is related to decreasing inflammatory markers, Hb1ac, and serum glucose. High levels of FA are also related to lower cardiometabolic risk in diabetic individuals.[46,55]

To evaluate the effectiveness of *L. fermentum*, the following sections refer to the findings on the antidiabetic properties of different strains of *L. fermentum*, investigated in preclinical and clinical studies.

**ANTI-DIABETIC PROPERTIES OF DIFFERENT STRAINS OF LIMOSILACTOBACILLUS FERMENTUM**

We investigated studies that analyzed the role of *L. fermentum* administered singly or combined with other therapies to alleviate DM complications. Among ten of the studies included, nine evaluated anti-diabetic properties in experimental studies using rats or mice. Only one clinical study assessed the anti-diabetic potential of probiotic intervention in women with gestational DM. Since the majority of beneficial effects following administration of *L. fermentum* come from animal studies, this present review investigated emerging findings of their potential role in DM management. The characteristics of the studies and the primary outcomes are summarized in Table 1 and Table 2, respectively.

*L. fermentum LLB3*

An experimental study revealed that treatment with *L. fermentum* LLB3 isolated from the bamboo shoot pickle and offered in fermented bitter melon (*Momordica charantia*), in a concentration of $1 \times 10^7$ CFU during 4 wk, reduced fasting glucose and postprandial blood glucose levels and increased SOD enzyme activity in rats subjected to type 2 DM
induced by streptozotocin (STZ)\textsuperscript{[57]}. This suggests that \textit{L. fermentum} LLB3 might be considered an adjuvant therapy to attenuate type 2 DM-related symptoms\textsuperscript{[57]}.

\textbf{\textit{L. fermentum} HP3}

Administration of a fermented \textit{Hericium erinaceus} juice containing 10\textsuperscript{9} CFU/mL of \textit{L. fermentum} HP3 for 12 wk reduced weight gain, increased insulin level, and reduced hyperglycemia in diabetic mice induced by STZ\textsuperscript{[58]}. In addition, treated mice showed lower levels of inflammatory cytokines, including IL-6, IL-17, and IFN-\gamma\textsuperscript{[58]}, suggesting that fermented \textit{Hericium erinaceus} juice can be used as nutritional manipulation in the treatment of type 2 DM.

\textbf{\textit{L. fermentum} ME-3}

A previous preclinical study investigated the anti-diabetic effect of \textit{L. fermentum} ME-3 in genetically diabetic mice\textsuperscript{[59]}. \textit{L. fermentum} ME-3 was administered in mice at 6 wk of age, in a concentration of 10\textsuperscript{10} CFU, for 12 wk\textsuperscript{[59]}. The treatment with \textit{L. fermentum} ME-3 reduced body weight, inhibited expression of TNF-\alpha, but did not improve glycemic control\textsuperscript{[59]}. In addition, supplementation with \textit{L. fermentum} ME-3 reduced the formation of glycation products, including FL-furosine levels in the kidney. However, the researchers found an increase in HbA1c, another marker of early glycation. The authors noted that while HbA1c reflects early glycation mainly in red blood cells, FL-furosine provides information on the extent of early glycation in fluids, tissues, and organs and offers a broader view of the early glycation status of the whole organism\textsuperscript{[59]}. In summary, \textit{L. fermentum} ME-3 has the therapeutic potential to reduce the formation of some glycation products in kidneys and attenuate some typical type 2 DM-related symptoms.

\textbf{\textit{L. fermentum} MCC2759 and MCC2760}

Recently, an Indian research group analyzed the activity of the probiotic \textit{L. fermentum} MCC2759 and MCC2760 on intestinal markers of inflammation using a high-fat diet
model associated with the STZ-induced diabetic model. Both _L. fermentum_ strains were administered in a concentration of 1 × 10^9 CFU/mL for 4 wk. The main findings of the study revealed that diabetic female rats treated with _L. fermentum_ MCC2759 and MCC2760 reduced blood glucose levels, increased insulin levels, and improved the lipid profile. Coupled with biochemical changes, _L. fermentum_ administration downregulated TNF-α mRNA and up-regulated mRNA IL-10 in the intestine, liver, mesenteric adipose tissue, and muscle, suggesting that the anti-diabetic effect promoted by _L. fermentum_ MCC2759 and MCC2760 can be associated with a decrease in inflammatory markers. In addition, _L. fermentum_ MCC2759 and MCC2760 administration modulated other gene expressions, such as reduced expression of Toll-like receptor 4, enhanced expression of tight junction protein ZO-1, endocannabinoid receptor CB2 and GLP1, glucose transporter type 4 in mesenteric adipose tissue and muscle tissue. The results demonstrated that _L. fermentum_ MCC2759 and MCC2760 might be a potential probiotic in treating type 2 DM.

**_L. fermentum_ MF423**

_L. fermentum_ MF423 is a strain isolated from Chinese rice noodle wastewater. The authors analyzed adverse effects triggered by an experimental model of type 2 DM induced by STZ and tested the effectiveness of different therapies, including supplementation with unfermented extracts of defatted rice bran, high and low doses of defatted rice bran fermented by _L. fermentum_ MF423, and drug intervention (pioglitazone). Mice receiving a high dose (1 g/kg) of defatted rice bran fermentation extracts containing _L. fermentum_ MF423 for 8 wk evidenced weight loss and reduced fasting blood glucose, lipid accumulation, and liver cells damage. Moreover, probiotic groups intensified antioxidant activity in diabetic mice through up-regulation levels of SOD, total antioxidant capacity (T-AOC), and reversed elevation of malondialdehyde (MDA) in the liver. It is important to mention that no effects were found in animals treated only by unfermented extracts of rice bran, highlighting the antioxidant activity of _L. fermentum_ MF423.
To complete the evaluation of the therapeutic potential of *L. fermentum* MF423, the authors investigated the role of this probiotic in the modulation of GM. Diabetic rats treated either to high dose of defatted rice fermented by *L. fermentum* or pioglitazone showed GM composition similar to the control group, compared to untreated diabetic animals.[32] The relative abundances of *Bacteroidetes* (20%) and *Firmicutes* (40%) were increased in both mentioned groups compared to a diabetic group without treatment.[32] A decreased abundance of *Firmicutes* can be found in diabetic patients compared to their non-diabetic counterparts.[60] These two major phyla may play an essential role in hyperglycemia, hyperlipidemia, and inflammation. Moreover, probiotic treatment increased the relative abundance of SCFA-producing bacteria in diabetic mice, including *Lactobacillus*, *Parabacteroides*, *norank_f_Ruminococcaceae*, *Ruminococcus_torques_group*, and *Alloprevotella*. Interestingly, a decrease in the genus *Lactobacillus* was significant in diabetic mice, while treatment with defatted rice bran fermented by *L. fermentum* MF423 increased its abundance, similar to control mice.[32] *L. fermentum* is known for its probiotic role in food consumption, which could modify abnormalities in intestinal microbes and retard hyperglycemia. In conclusion, defatted rice bran fermentation by *L. fermentum* MF423 Lessened damage to the structure and function of GM induced by type 2 DM.

*L. fermentum* MTCC: 5898

Probiotic fermented milk prepared using different probiotic strains, including *L. rhamnosus* MTCC: 5957, *L. rhamnosus* MTCC: 5897, and *L. fermentum* MTCC: 5898, were evaluated in an experimental study.[61] Probiotic strains were offered independently or in combination for treating STZ-induced type 1 DM in male *Wistar* rats. All probiotic strains were provided in a dosage of 1 × 10⁹ CFU for 6 wk. The study demonstrated that the diabetic rats who received fermented milk containing *L. fermentum* MTCC: 5898 had less weight loss, improved glucose metabolism by reducing fasting blood glucose, HbA1c associated with increased insulin level, reduced diabetic dyslipidemia, and attenuated inflammation status through reduction of IL-6 and TNF-α.[61] In addition,
supplementation with *L. fermentum* MTCC: 5898 showed antioxidant properties by increasing catalase (CAT) and SOD activities in the kidney and liver.[61] Moreover, administration of probiotics reduced mRNA expression of phosphoenolpyruvate carboxykinase and Glucose 6-phosphatase genes that code the key enzymes of the gluconeogenesis pathway.[61] Compared to other lactobacilli strains, rats receiving *L. fermentum* MTCC: 5898 displayed the most effective responses including oral glucose tolerance, serum insulin, serum, liver CAT, serum triglycerides, VLDL.[61] Therefore, it is suggested that daily consumption of probiotic fermented milk, especially *L. fermentum* MTCC: 5898, may be effective in attenuating complications of type 1 DM.

**L. fermentum** MTCC 5690 and MTCC 5689

*L. fermentum* MTCC 5690 and MTCC 5689 were isolated from the Indian gut and used to treat high-fat diet-induced type 2 DM mice[55]. The present study compared the antidiabetic effect of *L. fermentum* MTCC 5690 and MTCC 5689 to other probiotics (*Lactobacillus rhamnosus*, *Lactobacillus plantarum* MTCC5690) and drug intervention (metformin, vildagliptin). *L. fermentum* MTCC 5690 and MTCC 5689 were administered in a concentration of $1.5 \times 10^9$ colonies/mouse/day for 24 wk[55]. Both probiotics and drugs groups reduced body weight, improved oral glucose tolerance, and reduced fasting glucose and Hb1Ac levels in diabetic mice[55]. Concerning insulin levels, probiotic groups contributed to normalizing levels of this hormone, which approximated the levels observed in the control group[55]. In addition, a significant reduction of insulin levels was found in the vildagliptin group compared with other groups, which may be considered a possible adverse mild effect of this drug. Furthermore, all treatment groups improved lipid profile by reduction of levels of cholesterol, triglycerides, LDL, associated with an increase in HDL levels.

Additionally, the study evaluated the gut integrity after 24 wk of treatment. Probiotic treatment and drug therapy were able to reduce damage in gut integrity, which may contribute to normalizing gut permeability[55]. The authors quantified mRNA expression of epithelial tight junction occludin and ZO-1 and LPS levels. All the
probiotic and anti-diabetic drugs increased gene expression of the intestinal tight junction occludin and ZO-1\cite{55}. To evaluate endotoxia state and intestinal barrier integrity, probiotic treatments decreased LPS levels and pro-inflammatory cytokines IL-6 and TNF-α in mice subjected to type 2 DM\cite{55}. In addition, the authors verified the effectiveness of treatments in attenuating endoplasmic reticulum stress of skeletal muscle of diabetic mice. Results showed that both probiotic and drug therapies reduced endoplasmic reticulum stress markers\cite{55}. The findings suggested that *L. fermentum* MTCC 5690 and MTCC 5689 act like anti-diabetic drugs, highlighting the therapeutic potential of these probiotic strains in alleviating type 2 DM complications.

**Non mentioned strain of L. fermentum**

The role of *L. fermentum* fruit extracts of *Syzygium cumini* and *Momordica charantia*, isolated from yogurt samples (Pakistan) on STZ induced DM mice, was previously investigated\cite{53}. *L. fermentum* and the extracts were administered individually as well as in combination with DM-induced mice for 3 wk. Results were compared with mice that received drug intervention (Glucophage). Administration of probiotics and natural extracts improved body weight, and reduced blood glucose levels and both results were similar with the Glucophage group\cite{53}. Concerning lipid profile, *L. fermentum* and natural extracts improved almost all lipid profile parameters, including reduced triglycerides, LDL, and increased HDL serum levels\cite{53}. The study demonstrated that Glucophage treatment might affect some parameters, such as increased total cholesterol, triglycerides, and LDL concentration. These findings showed that *L. fermentum* and natural extracts have hypoglycemic and hypolipidemic activity, which may reduce DM complications.

Another experimental study demonstrated that mixed probiotics containing *L. fermentum* could reverse insulin resistance, reduce blood glucose levels, and improve lipid profile in STZ induced DM in old male Kunming mice after 4 wk of treatment\cite{33}. In addition, the authors showed a significant impact of the supplementation of *L. fermentum* on the relief of gut dysbiosis, lowering the damage in the composition of
GM[33]. However, the authors did not specify which strain of *L. fermentum* was administered, limiting the understanding of these effects.

Regarding clinical data, we found only one randomized, double-blind, placebo-controlled trial that evaluated the effectiveness of *L. fermentum* in attenuating complications of DM[31]. This study was carried out to assess the effects of probiotic supplementation on genetic and metabolic profiles in patients with gestational DM, aged 18-40 years (at weeks 24-28 of gestation)[31]. Participants were randomly divided into two groups: a control group and a probiotic group, made up of women who received a probiotic capsule containing *Lactobacillus acidophilus*, *Lactobacillus casei*, *Bifidobacterium bifidum*, *L. fermentum* (2 × 10⁹ CFU/g each) for 6 wk[31]. However, the authors did not inform the specific strain of *L. fermentum* used, limiting the interpretation of results. The probiotic group showed lower levels of fasting blood glucose serum insulin, reduced insulin resistance, and significantly increased insulin sensitivity compared with the control group[31]. In addition, probiotic supplementation decreased triglycerides, VLDL, and increased HDL levels compared with the control group. Additionally, probiotic administration reduced plasma MDA, and an elevation in plasma nitric oxide and T-AOC was found compared with the control group. Therefore, the probiotic treatment showed great therapeutic potential in alleviating complications found in women with gestational DM. Future clinical studies are needed to investigate further the specific strains of *L. fermentum* to elucidate which strains are more effective in attenuated DM.

**CONCLUSION**

This literature review showed that *L. fermentum* is a promising strain for the management of DM (Figure 1). Evidence from experimental and clinical study verified that *L. fermentum* supplementation contributed to normalizing body weight, reduced blood glucose and fasting blood glucose levels, reduced insulin resistance, and improved lipid profile. Coupled with these biochemical changes, *L. fermentum* therapy showed anti-oxidant and anti-inflammatory properties, which contributed to alleviating
related symptoms of DM. However, the heterogeneities of studies, including variations in dosage, and duration of treatment, limit the elucidation of the most effective way to use *L. fermentum* as adjuvant therapy of DM. Moreover, it is relevant to explore the effectiveness of co-intervention with *L. fermentum* associated with bioactive compounds with antioxidant and anti-inflammatory properties, such as quercetin and resveratrol\(^{[15,62]}\). We also highlight that most of the available data came from preclinical studies, hence, therapeutic potential of different strains of *L. fermentum* in minimizing complications of DM needs to be further investigated in randomized, double-blind, placebo-controlled trials to confirm these findings in human studies.
<table>
<thead>
<tr>
<th></th>
<th>Source</th>
<th>Words</th>
<th>Similarity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>117</td>
<td>3%</td>
</tr>
<tr>
<td>2</td>
<td>Axel Guilbaud, Michael Howsam, Céline Niquet - Léridon, Florian Delgust et al. &quot;The Effect of ME-3 Treatment on Glycation and Diabetes Complications&quot;, Molecular Nutrition &amp; Food Research, 2020</td>
<td>52</td>
<td>1%</td>
</tr>
<tr>
<td>3</td>
<td>link.springer.com</td>
<td>39</td>
<td>1%</td>
</tr>
<tr>
<td>4</td>
<td><a href="http://www.researchgate.net">www.researchgate.net</a></td>
<td>35</td>
<td>1%</td>
</tr>
<tr>
<td>5</td>
<td>Diego Cabral Lacerda, Paulo César Trindade Costa, Yohanna de Oliveira, José Luiz de Brito Alves. &quot;The effect of resveratrol in cardio-metabolic disorders during pregnancy and offspring outcomes: a review&quot;, Journal of Developmental Origins of Health and Disease, 2022</td>
<td>33</td>
<td>1%</td>
</tr>
<tr>
<td>No.</td>
<td>Author(s)</td>
<td>Title</td>
<td>Journal/Source</td>
</tr>
<tr>
<td>-----</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7</td>
<td>Mahalingam Balakumar, Durai Prabhu, Chandrakumar Sathishkumar, Paramasivam Prabu et al.</td>
<td>&quot;Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice&quot;, European Journal of Nutrition, 2016</td>
<td>Crossref</td>
</tr>
<tr>
<td>8</td>
<td>Luciana Caroline Paulino do Nascimento, Diego Cabral Lacerda, Diorginis José Soares Ferreira, Evandro Leite de Souza et al.</td>
<td>&quot;Limosilactobacillus fermentum, Current Evidence on the Antioxidant Properties and Opportunities to be Exploited as a Probiotic Microorganism&quot;, Probiotics and Antimicrobial Proteins, 2022</td>
<td>Crossref</td>
</tr>
<tr>
<td>9</td>
<td>docplayer.net</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>mafiadoc.com</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td><a href="http://www.mdpi.com">www.mdpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td><a href="http://www.tandfonline.com">www.tandfonline.com</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>